FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220690711> ?p ?o ?g. }

• W4220690711 endingPage "2713" @default.
• W4220690711 startingPage "2705" @default.
• W4220690711 abstract "Eradication of poliomyelitis globally is constrained by fecal shedding of live polioviruses, both wild-type and vaccine-derived strains, into the environment. Although inactivated polio vaccines (IPV) effectively protect the recipient from clinical poliomyelitis, fecal shedding of live virus still occurs following infection with either wildtype or vaccine-derived strains of poliovirus. In the drive to eliminate the last cases of polio globally, improvements in both oral polio vaccines (OPV) (to prevent reversion to virulence) and injectable polio vaccines (to improve mucosal immunity and prevent viral shedding) are underway. The E. coli labile toxin with two or “double” attenuating mutations (dmLT) may boost immunologic responses to IPV, including at mucosal sites. We performed a double-blinded phase I controlled clinical trial to evaluate safety, tolerability, as well as systemic and mucosal immunogenicity of IPV adjuvanted with dmLT, given as a fractional (1/5th) dose intradermally (fIPV-dmLT). Twenty-nine volunteers with no past exposure to OPV were randomized to a single dose of fIPV-dmLT or fIPV alone. fIPV-dmLT was well tolerated, although three subjects had mild but persistent induration and hyperpigmentation at the injection site. A ≥ 4-fold rise in serotype-specific neutralizing antibody (SNA) titers to all three serotypes was seen in 84% of subjects receiving fIPV-dmLT vs. 50% of volunteers receiving IPV alone. SNA titers were higher in the dmLT-adjuvanted group, but only differences in serotype 1 were significant. Mucosal immune responses, as measured by polio serotype specific fecal IgA were minimal in both groups and differences were not seen. fIPV-dmLT may offer a benefit over IPV alone. Beyond NAB responses protecting the individual, studies demonstrating the ability of fIPV-dmLT to prevent viral shedding are necessary. Studies employing controlled human infection models, using monovalent OPV post-vaccine are ongoing. Studies specifically in children may also be necessary and additional biomarkers of mucosal immune responses in this population are needed. Clinicaltrials.gov Identifer: NCT03922061." @default.
• W4220690711 created "2022-04-03" @default.
• W4220690711 creator A5002707102 @default.
• W4220690711 creator A5010472783 @default.
• W4220690711 creator A5022384962 @default.
• W4220690711 creator A5022694290 @default.
• W4220690711 creator A5030036092 @default.
• W4220690711 creator A5050267368 @default.
• W4220690711 creator A5052395287 @default.
• W4220690711 creator A5079543026 @default.
• W4220690711 creator A5090086410 @default.
• W4220690711 date "2022-04-01" @default.
• W4220690711 modified "2023-10-03" @default.
• W4220690711 title "Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized placebo-controlled trial" @default.
• W4220690711 cites W1839545847 @default.
• W4220690711 cites W1968878008 @default.
• W4220690711 cites W1970906496 @default.
• W4220690711 cites W1971110767 @default.
• W4220690711 cites W1981655353 @default.
• W4220690711 cites W2041267012 @default.
• W4220690711 cites W2065709887 @default.
• W4220690711 cites W2071254911 @default.
• W4220690711 cites W2072031338 @default.
• W4220690711 cites W2082011551 @default.
• W4220690711 cites W2091763807 @default.
• W4220690711 cites W2097965467 @default.
• W4220690711 cites W2102060315 @default.
• W4220690711 cites W2103683759 @default.
• W4220690711 cites W2109715645 @default.
• W4220690711 cites W2123407575 @default.
• W4220690711 cites W2133080338 @default.
• W4220690711 cites W2155116147 @default.
• W4220690711 cites W2158564014 @default.
• W4220690711 cites W2217538693 @default.
• W4220690711 cites W2218699516 @default.
• W4220690711 cites W2396524001 @default.
• W4220690711 cites W2515706651 @default.
• W4220690711 cites W2734746513 @default.
• W4220690711 cites W2735088147 @default.
• W4220690711 cites W2735657752 @default.
• W4220690711 cites W2735907711 @default.
• W4220690711 cites W2736278021 @default.
• W4220690711 cites W2742771956 @default.
• W4220690711 cites W2781617550 @default.
• W4220690711 cites W2857942840 @default.
• W4220690711 cites W2902016030 @default.
• W4220690711 cites W2905307876 @default.
• W4220690711 cites W2948253547 @default.
• W4220690711 cites W2951412666 @default.
• W4220690711 cites W2967133601 @default.
• W4220690711 cites W2970335474 @default.
• W4220690711 cites W2986629155 @default.
• W4220690711 cites W2987789766 @default.
• W4220690711 cites W3019647694 @default.
• W4220690711 cites W3093042074 @default.
• W4220690711 cites W3111877257 @default.
• W4220690711 cites W3182065026 @default.
• W4220690711 cites W3195353462 @default.
• W4220690711 cites W3214436431 @default.
• W4220690711 cites W4205696221 @default.
• W4220690711 cites W4210691393 @default.
• W4220690711 cites W4231313931 @default.
• W4220690711 cites W4254537929 @default.
• W4220690711 cites W4384466965 @default.
• W4220690711 doi "https://doi.org/10.1016/j.vaccine.2022.03.056" @default.
• W4220690711 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35367069" @default.
• W4220690711 hasPublicationYear "2022" @default.
• W4220690711 type Work @default.
• W4220690711 citedByCount "7" @default.
• W4220690711 countsByYear W42206907112023 @default.
• W4220690711 crossrefType "journal-article" @default.
• W4220690711 hasAuthorship W4220690711A5002707102 @default.
• W4220690711 hasAuthorship W4220690711A5010472783 @default.
• W4220690711 hasAuthorship W4220690711A5022384962 @default.
• W4220690711 hasAuthorship W4220690711A5022694290 @default.
• W4220690711 hasAuthorship W4220690711A5030036092 @default.
• W4220690711 hasAuthorship W4220690711A5050267368 @default.
• W4220690711 hasAuthorship W4220690711A5052395287 @default.
• W4220690711 hasAuthorship W4220690711A5079543026 @default.
• W4220690711 hasAuthorship W4220690711A5090086410 @default.
• W4220690711 hasBestOaLocation W42206907111 @default.
• W4220690711 hasConcept C10389963 @default.
• W4220690711 hasConcept C104317684 @default.
• W4220690711 hasConcept C12914427 @default.
• W4220690711 hasConcept C159047783 @default.
• W4220690711 hasConcept C159654299 @default.
• W4220690711 hasConcept C203014093 @default.
• W4220690711 hasConcept C2522874641 @default.
• W4220690711 hasConcept C2777871010 @default.
• W4220690711 hasConcept C2779261636 @default.
• W4220690711 hasConcept C2779631682 @default.
• W4220690711 hasConcept C2780868878 @default.
• W4220690711 hasConcept C2908689829 @default.
• W4220690711 hasConcept C4870876 @default.
• W4220690711 hasConcept C547475151 @default.
• W4220690711 hasConcept C55493867 @default.
• W4220690711 hasConcept C66999527 @default.
• W4220690711 hasConcept C71924100 @default.

• next